Abstract Details

Title Prevalence of alpha-Delta Sleep in Postural Orthostatic Tachycardia Syndrome

Topic Autonomic Disorders

Presentation(s) P03 - (-)

Poster/Presentation
Number 038

Objective

Background BACKGROUND: POTS is defined as symptomatic orthostatic intolerance associated with a heart rate increase of 30 bpm (or exceeding 120 bpm) occurring within the first 10 minutes of standing or upright tilt, that is not associated with other chronic debilitating conditions such as prolonged bed rest or the use of medications known to diminish vascular or autonomic tone. Patients with POTS complain of symptoms such as non-restorative sleep and daytime sleepiness. Alpha-delta sleep (ADS) is described as alpha wave intrusions in delta NREM (N3) sleep. ADS has been described in patients with fibromyalgia and depression - populations that share similar sleep complaints with POTS patients. We hypothesized that ADS would be observed in patients with POTS.

Design/Methods DESIGN/METHODS: Polysomnograms from patients diagnosed with POTS (n=5, women=100%) were retrospectively analyzed by one sleep medicine specialist for the percent of delta waves with alpha intrusion during NREM sleep. Sleep efficiency and Epworth Sleepiness Scale (ESS) were also measured. None of the patients had a history of fibromyalgia or depression.

Results RESULTS: All patients had alpha intrusions in N3 sleep. ADS constituted a mean of 7.22% with a range of 3-16% of N3 sleep. Sleep efficiency was decreased in all patients. Those with greater sleep efficiency had a lower percentage of ADS. No correlation was observed between ESS and ADS.

Conclusions CONCLUSIONS: ADS is an abnormal finding in sleep. To our knowledge this is the first description of presence of ADS in POTS patients. Daytime sleepiness did not correlate with ADS but an inverse correlation was noted between ADS and sleep efficiency. Further investigation is needed to characterize and evaluate the clinical implications given the limited sample size.

Authors/Disclosures
Okeanis Vaou, MD, FAAN (UT San Antonio) PRESENTER	Dr. Vaou has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ABBVIE. Dr. Vaou has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Vaou has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic . Dr. Vaou has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for medtronic. An immediate family member of Dr. Vaou has stock in SAGE. The institution of Dr. Vaou has received research support from Medtronic.
Andrew J. Westwood, MD, FAAN	Dr. Westwood has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Healthcare Business Solutions UK. Dr. Westwood has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda.
Yelena G. Pyatkevich, MD (Takeda Pharmaceutical)	Dr. Pyatkevich has received personal compensation for serving as an employee of Takeda. Dr. Pyatkevich has stock in Takeda.
Sanford H. Auerbach, MD, FAAN (Boston University Medical Center)	Dr. Auerbach has nothing to disclose.
Anna D. Hohler, MD, FAAN (Steward SEMC)	Dr. Hohler has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��